Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

ACTIVE_NOT_RECRUITING

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

Chronic Inducible Urticaria

Eligibility:

All Genders

18-100 years

Phase:

PHASE3

Brief Summary

This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE). The purpose of the core period (52 weeks o...

Detailed Description

This study consists of a core and extension periods. The Core period (6 arms) has a total duration of up to 60 weeks including a double-blind placebo-controlled treatment period until Week 24 followe...

Eligibility Criteria

Inclusion

  • Inclusion Criteria for core period:
  • Male and female participants ≥18 years of age at the time of signing of the ICFs
  • Confirmed CINDU diagnosis (as per guidelines) for symptomatic dermographism, cold urticaria or cholinergic urticaria for ≥ 4 months (defined as onset of CINDU with supporting documentation (e.g medical record, clinical history, photographs)) and inadequate control with H1-AH at local label approved doses at the time of randomization
  • The following response to the provocation test for each subtype is required at the randomization visit :
  • Symptomatic Dermographism: A Total Fric Score of ≥3 using the FricTest® 4.0 and a numerical rating scale score of ≥5 for itch after the provocation test.
  • Cold Urticaria: A Critical Threshold Temperature of ≥15°C using the TempTest® 4.0 and a numerical rating scale score of ≥5 for itch after the provocation test.
  • Cholinergic Urticaria: A physician global assessment of severity of hives ≥ 2 using the Pulse-controlled ergometry test and a numerical rating scale score of ≥5 for itch after the provocation test.
  • Cold Urticaria: Positive ice-cube test resulting in hives at the provocation site for participants at Screening.
  • Cholinergic urticaria: Participants must show sweating in performing the pulse-controlled ergometry test on day of randomization. Participants with anhidrosis must not be included.
  • Inclusion criteria for the OLE:
  • Participants who have completed the Core period up to Week 52 and are willing to enter the OLE period
  • Exclusion Criteria for core period:
  • 1\. Previous use of remibrutinib or other BTK inhibitors.
  • Participants who have concomitant CSU at screening. Participants with resolved CSU at the time of screening can be included in the study.
  • Participants who have a familial form (e.g familial cold autoinflammatory syndrome, familial cold urticaria) of the target CINDU that is being considered for the participant's inclusion in this study.
  • Participants having a more defined other form of inducible urticaria than the target CINDU that is being considered for the participant's inclusion in this study.
  • Diseases, other than chronic inducible urticaria, with urticaria or angioedema symptoms including but not limited to urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa) and hereditary or acquired angioedema
  • Any other skin disease associated with chronic itching that might influence, in the investigator's opinion, the study evaluations and results (e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, etc.) or skin diseases associated with only wheals and no itch e.g asymptomatic dermographism
  • There are no exclusion criteria for OLE

Exclusion

    Key Trial Info

    Start Date :

    December 7 2023

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    August 1 2028

    Estimated Enrollment :

    364 Patients enrolled

    Trial Details

    Trial ID

    NCT05976243

    Start Date

    December 7 2023

    End Date

    August 1 2028

    Last Update

    December 22 2025

    Active Locations (134)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 34 (134 locations)

    1

    Allervie Clinical Research

    Birmingham, Alabama, United States, 35209

    2

    Acuro Research Inc

    Little Rock, Arkansas, United States, 72205

    3

    Kern Research

    Bakersfield, California, United States, 93301

    4

    Allergy and Asthma Specialists Group

    Huntington Beach, California, United States, 92647